09:54 AM EDT, 07/29/2024 (MT Newswires) -- GSK (GSK) is partnering with bioplatform company Flagship Pioneering to identify and develop new medicines and vaccines, starting with prospective respiratory and immunology treatments, Flagship said Monday.

The deal calls for GSK and Flagship to put $150 million toward an exploratory phase that would identify the ten most promising prospective medicines and vaccines for further research and development, Flagship said.

GSK will receive exclusive options to work on each of the new drug candidates found during the discovery phase, with Flagship eligible for up to $720 million in milestone payments, as well as preclinical funding and tiered royalties, for each of the development programs acquired by GSK, Flagship said.

Price: 40.00, Change: +0.14, Percent Change: +0.35